Skip to main content

Table 4 Sensitivity and specificity of sAxl in CSF and plasma to discriminate between RIA and UIA

From: Identification of the soluble form of tyrosine kinase receptor Axl as a potential biomarker for intracranial aneurysm rupture

sAxl in CSF (n = 30/group)

Cut off (nM)

Sensitivity % (95% CI)

Specificity % (95% CI)

LR+

LR-

0.02

100.00 (88.43 to 100.00)

13.33 (3.76 to 30.72)

1.15

0.00

0.09

90.00 (73.47 to 97.89)

66.67 (47.19 to 82.71)

2.70

0.15

0.10

86.67 (69.28 to 96.24)

70.00 (50.60 to 85.27)

2.89

0.19

0.11

76.67 (57.72 to 90.07)

83.33 (65.28 to 94.36)

4.60

0.28

0.12

73.33 (54.11 to 87.72)

90.00 (54.11 to 87.72)

7.33

0.30

0.14

63.33 (43.86 to 80.07)

93.33 (77.93 to 99.18)

9.50

0.39

sAxl in plasma (n = 20/group)

Cut off (nM)

Sensitivity % (95% CI)

Specificity % (95% CI)

LR+

LR-

0.4

100 (83.16 to 100.0)

5 (0.1265 to 24.87)

1.05

0.00

0.5

90 (68.30 to 98.77)

15 (3.207 to 37.89)

1.06

0.67

1

80 (56.34 to 94.27)

45 (23.06 to 68.47)

1.45

0.44

1.2

65 (40.78 to 84.61)

65 (40.78 to 84.61)

1.86

0.54

1.7

50 (27.20 to 72.80)

80 (56.34 to 94.27)

2.50

0.63

  1. 95% CI, 95% confidence interval; LR+, positive likelihood ratio; LR-, negative likelihood ratio.